Purdue Palladone Risk Management Documents Requested By House Cmte.
Executive Summary
Purdue Pharma will submit documents relating to risk management for its pending pain therapy Palladone to the House Energy & Commerce Committee
You may also be interested in...
Purdue Palladone Phased Launch To Begin In First Half 2005
Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005
Purdue Palladone Phased Launch To Begin In First Half 2005
Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005
Congress’ Oxycontin concerns continue
Reps. Frank Wolf (R-Va), Jim Greenwood (R- Pa), Henry Bonilla (R-Texas) and Harold Rogers (R- Ky) meet with FDA Commissioner McClellan April 3 to discuss abuse of Purdue's OxyContin (oxycodone). Wolf sent a letter to HHS Secretary Thompson March 28 asking that OxyContin treatment be limited to patients with severe pain. The House Energy & Commerce committee is investigating OxyContin and Purdue's Palladone, a pain therapy pending at FDA (1"The Pink Sheet" March 3, p. 33)...